A Phase I Randomized Placebo Controlled Study of a Virosome Formulated Anti-Candida Vaccine (PEV7) Administered by the Vaginal (PEV7A) or Intramuscular (PEV7B) Route to Healthy Adult Volunteers.
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2012
At a glance
- Drugs Candida vaccine (Primary)
- Indications Vulvovaginal candidiasis
- Focus Adverse reactions; Pharmacodynamics
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Oct 2012 Planned End Date changed from 1 Apr 2013 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 12 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.